D.E. Shaw & Co
PGEN icon

D.E. Shaw & Co’s Precigen PGEN Stock Holding History

D.E. Shaw & Co’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,393
Closed -$311K – 3691
2015
Q4 		$311K Hold
10,393
– – ﹤0.01% 3348
2015
Q3 		$328K Hold
10,393
– – ﹤0.01% 3311
2015
Q2 		$503K Buy
+10,393
New +$438K ﹤0.01% 3163

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

D.E. Shaw & Co's PGEN Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Precigen (PGEN) in Q1 2025, closing a stake of 424,900 shares — an estimated $476K sold.

D.E. Shaw & Co first reported a position in PGEN in Q4 2013 and held it in 40 quarters. The position peaked at $11.1M in Q2 2017. 138 funds tracked by Wall St. Rank hold PGEN as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Precigen position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 424,900 Precigen shares in Q1 2025, an estimated $476K.
  • D.E. Shaw & Co first reported a position in Precigen in Q4 2013 and held it in 40 quarters.
  • D.E. Shaw & Co's Precigen position peaked at $11.1M in Q2 2017.
  • 138 funds tracked by Wall St. Rank held Precigen as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.